Cargando…
Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
The use of Bruton’s tyrosine kinase (BTK) inhibitors has changed the management of patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects B-cell antigen receptor (BCR) signaling. BTK inhibitors (BTKis) are classified into three categories, namely covalent irrever...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145705/ https://www.ncbi.nlm.nih.gov/pubmed/35628931 http://dx.doi.org/10.3390/jcm11102807 |
_version_ | 1784716381075275776 |
---|---|
author | Robak, Ewa Robak, Tadeusz |
author_facet | Robak, Ewa Robak, Tadeusz |
author_sort | Robak, Ewa |
collection | PubMed |
description | The use of Bruton’s tyrosine kinase (BTK) inhibitors has changed the management of patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects B-cell antigen receptor (BCR) signaling. BTK inhibitors (BTKis) are classified into three categories, namely covalent irreversible inhibitors, covalent reversible inhibitors, and non-covalent reversible inhibitors. Ibrutinib is the first covalent, irreversible BTK inhibitor approved in 2013 as a breakthrough therapy for chronic lymphocytic leukemia patients. Subsequently, two other covalent, irreversible, second-generation BTKis, acalabrutinib and zanubrutinib, have been developed for lymphoid malignancies to reduce the ibrutinib-mediated adverse effects. More recently, irreversible and reversible BTKis have been under development for immune-mediated diseases, including autoimmune hemolytic anemia, immune thrombocytopenia, multiple sclerosis, pemphigus vulgaris, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s disease, and chronic spontaneous urticaria, among others. This review article summarizes the preclinical and clinical evidence supporting the role of BTKis in various autoimmune, allergic, and inflammatory conditions. |
format | Online Article Text |
id | pubmed-9145705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91457052022-05-29 Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives Robak, Ewa Robak, Tadeusz J Clin Med Review The use of Bruton’s tyrosine kinase (BTK) inhibitors has changed the management of patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects B-cell antigen receptor (BCR) signaling. BTK inhibitors (BTKis) are classified into three categories, namely covalent irreversible inhibitors, covalent reversible inhibitors, and non-covalent reversible inhibitors. Ibrutinib is the first covalent, irreversible BTK inhibitor approved in 2013 as a breakthrough therapy for chronic lymphocytic leukemia patients. Subsequently, two other covalent, irreversible, second-generation BTKis, acalabrutinib and zanubrutinib, have been developed for lymphoid malignancies to reduce the ibrutinib-mediated adverse effects. More recently, irreversible and reversible BTKis have been under development for immune-mediated diseases, including autoimmune hemolytic anemia, immune thrombocytopenia, multiple sclerosis, pemphigus vulgaris, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s disease, and chronic spontaneous urticaria, among others. This review article summarizes the preclinical and clinical evidence supporting the role of BTKis in various autoimmune, allergic, and inflammatory conditions. MDPI 2022-05-16 /pmc/articles/PMC9145705/ /pubmed/35628931 http://dx.doi.org/10.3390/jcm11102807 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Robak, Ewa Robak, Tadeusz Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives |
title | Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives |
title_full | Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives |
title_fullStr | Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives |
title_full_unstemmed | Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives |
title_short | Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives |
title_sort | bruton’s kinase inhibitors for the treatment of immunological diseases: current status and perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145705/ https://www.ncbi.nlm.nih.gov/pubmed/35628931 http://dx.doi.org/10.3390/jcm11102807 |
work_keys_str_mv | AT robakewa brutonskinaseinhibitorsforthetreatmentofimmunologicaldiseasescurrentstatusandperspectives AT robaktadeusz brutonskinaseinhibitorsforthetreatmentofimmunologicaldiseasescurrentstatusandperspectives |